MAIA Biotechnology, Inc. (MAIA) Stock Price
MAIAStock
$1.33−12.50%52W
Market Cap$80.91M
P/E—
PEG Ratio—
Div yield—
Beta0.26
MAIA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-56.97%
Price vs S&P 500 (4W)-0.78%
VGM Score44.63
MAIA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.11 | -$0.13 | -18.18%(-$0.02) | |
| Q1 2026 | -$0.18 | -$0.14 | +22.22%(+$0.04) | |
| Q4 2025 | -$0.13 | -$0.14 | -5.23%(-$0.01) | |
| Q3 2025 | -$0.19 | -$0.27 | -42.11%(-$0.08) | |
| Q2 2025 | -$0.25 | -$0.17 | +32.84%(+$0.08) |
MAIA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MAIAMAIA Biotechnology, Inc. | — | — | C | $1.33 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About MAIA Biotechnology, Inc.
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing THIO, an investigational drug candidate with dual anti-cancer mechanisms targeting telomeres and immune function. The lead program combines THIO with Regeneron's approved checkpoint inhibitor Libtayo (cemiplimab) to treat patients with advanced non-small cell lung cancer. The combination approach aims to enhance the immune system's ability to attack cancer cells.